Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores

BMC Medical Research Methodology

Yan Chen¹  Taobo Hu²  Danhua Zhang³  Jiankang Pan⁴  Yiqiang Liu⁵  Mengping Long⁵ 

[1] College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China;Department of Breast Disease, Peking University People’s Hospital, Beijing, China;Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;Department of Pathology, Peking University Cancer Hospital, Beijing, China;

关键词: Estrogen receptor, Progesterone receptor;    Pathway activities;    LASSO;    Growth factor;   

DOI  :  10.1186/s12874-021-01297-8

来源: Springer

【 摘 要 】

PurposePR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed.MethodsIn this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathways were analyzed and used as variables for classifying the two groups with LASSO regression.ResultsER+/PR+/HER2- and ER+/PR-/HER2- breast cancer groups can be classified by a combination of 13 pathways using their activity score. Among the 13 pathways, those involving growth factors and ion-channel transporters were most significant in the distinction, followed by pathways involving immune modulation and cell metabolism. Two growth factor pathways, EGF and IGF-1, were deferentially regulated in ER+/PR+/HER2- and ER+/PR-/HER2- groups.ConclusionsIn conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation.

【 授权许可】

CC BY